Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
If you prefer the injectable route, Tirzepatide Injection ($289/mo) covers the same molecule at 2.5mg15mg weekly
You may be eligible for this study if you: Have been diagnosed with type 2 diabetes Have confirmed atherosclerotic cardiovascular disease (a buildup of plaque from atherosclerosis in your blood vessels that can damage your heart and other organs) Have an A1C between 7% and 10.5% Have a BMI greater or equal to 25 kg/m2 Are at least 40 years old Have not had a major cardiovascular event in the last 60 days Do not have a history of severe hypoglycemia and/or hypoglycemia unawareness within the last 6 months If you have had a prior health event such as heart attack, stroke, or angina, or confirmed evidence of damage to the arteries from fatty plaques, contact the number below to find out if you are eligible You can see a full list of eligibility and exclusion criteria here
Who is not suitable for NAD+ IV therapy
Tesofensine is significantly less expensive per subject in research settings because its an oral small-molecule compound stable at room temperature, while cagrilintide is a synthetic peptide requiring lyophilisation, refrigerated storage, and weekly injection supplies
